FDA declines to review Moderna's mRNA flu shot

Original Article ↗ Hacker News Discussion ↗

Scope of the FDA Decision & Trial Design Dispute

  • Commenters highlight that FDA’s stated issue is the trial comparator: Moderna used a standard flu shot, while for 65+ the “best available standard of care” is higher‑dose or adjuvanted vaccines.
  • Some argue the agency simply wants the control arm to match current CDC guidance for older adults.
  • Others suspect this is a pretext (“sandbagging”), noting trial designs are usually shaped in consultation with regulators and prior CDC communication suggested this might affect recommendations for 65+, not overall approval.

Effect on Flu Vaccination and Target Populations

  • Multiple comments stress that flu vaccines remain widely available; this affects only this mRNA product.
  • The main immediate impact is on people 65+ and those with preexisting conditions; younger adults are mostly unaffected.
  • There’s concern that not approving potentially more effective or faster‑to‑update mRNA vaccines could slow progress against evolving flu strains.

Politics, RFK Jr., and Regulatory Interference

  • Several see this as a political move influenced by anti‑mRNA activism, specifically tying it to RFK Jr.’s agenda.
  • Others focus blame on “this administration” more broadly, arguing the decision overrode a pro‑innovation FDA head for political optics.

Mandates, Backlash, and Public Health Tradeoffs

  • Long subthreads debate whether Covid vaccine mandates and messaging “burned a century of goodwill,” fueling wider vaccine skepticism (measles, etc.).
  • One side emphasizes societal benefits of vaccination (reduced hospital burden, protection of the immunocompromised, economic externalities).
  • The opposing side stresses bodily autonomy and questions using collective cost savings to justify mandates, comparing vaccines to obesity, smoking, and drug use as public‑health burdens.
  • There is disagreement over whether herd immunity for Covid was ever realistic and whether that undercuts mandate justifications.

Future of mRNA & Broader Trust Debates

  • Some fear this decision will slow mRNA innovation, including future cancer vaccines; others note ongoing non‑flu mRNA cancer trials elsewhere.
  • A long meta‑discussion centers on “do your own research”:
    • One camp criticizes it as code for consuming low‑quality social media content and conspiracy theories.
    • Another argues declining institutional trust and censorship make independent inquiry necessary, even if imperfect.